FIELD: pharmaceutical chemistry.
SUBSTANCE: group of inventions relates to pharmaceutical chemistry and includes a compound with formula (I), (II), specific compounds indicated in the claims, their use, as well as a pharmaceutical composition and an inhibition method based thereon. In formula (I) X1 - X4 independently refer to CR0 or N, where at least two of X1 - X4 are CR0, R0 is independently H or halogen, R1 is linear or branched -C1-5 haloalkyl, R2 and R3 are all independently H, halogen, , 3-7-membered heterocycloalkyl containing from 1 to 3 heteroatoms selected from the group including N, O or S, 3-7-membered heterocycloalkenyl containing from 1 to 3 heteroatoms selected from the group including N, O or S , 5- or 6-membered heteroaryl containing from 1 to 3 heteroatoms selected from the group consisting of N, O or S,
,
,
,
,
, phenyl, indolyl or
, K is O or S, Y is CRa Rb, NRc or a single bond, Ra and Rb are all independently hydrogen or -C 1-7 alkyl or Ra and Rb are bonded to each other and form a 3- 7-membered cycloalkyl, ring A is phenylene, n is 0 or 1, other substituents are as defined in the claims. In formula (II), X1 - X4 are independently CR 0 or N, where at least two of X1 - X4 are CR 0, where R0 is H, R 1 is linear or branched -C 1-5 haloalkyl , R2 and R3 are all independently H, K is O, Y is NRc, Rc is -C1-7 alkylphenyl, -C1-7 alkylheteroaryl, in which case heteroaryl is 5- or 6-membered heteroaryl , containing from 1 to 3 heteroatoms selected from the group consisting of N, O or S, or -C 1-7 alkyl-OC 1-7 alkyl, where one H atom of the group is -C1-7 alkylheteroaryl, in this case heteroaryl is a 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from the group consisting of N, O or S, may be substituted by the following substituent: heteroaryl-C1-5 haloalkyl, in which case heteroaryl is 5- or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from the group consisting of N, O or S, ring A is phenylene, n is 0 or 1.
EFFECT: 1,3,4-oxadiazole derivatives having the properties of a highly selective HDAC6 inhibitor.
12 cl, 2 tbl, 1 ex
Title | Year | Author | Number |
---|---|---|---|
1,3,4-OXADIAZOLE DERIVATIVES AS HISTONE DEACETYLASE 6 INHIBITOR AND PHARMACEUTICAL COMPOSITION CONTAINING THEM | 2019 |
|
RU2763936C1 |
1,3,4-OXADIAZOLE DERIVATIVES AS HISTONE DEACETYLASE 6 INHIBITOR AND PHARMACEUTICAL COMPOSITION CONTAINING THEREOF | 2021 |
|
RU2822180C1 |
1,3,4-OXADIAZOLE SULPHAMIDE DERIVATIVES AS HISTONE DEACETYLASE 6 INHIBITOR AND PHARMACEUTICAL COMPOSITION CONTAINING THEM | 2016 |
|
RU2695227C1 |
1,3,4-OXADIAZOLE DERIVATIVES AS HISTONE DEACETYLASE 6 INHIBITOR AND PHARMACEUTICAL COMPOSITION CONTAINING THEM | 2021 |
|
RU2810081C1 |
1,3,4-OXADIAZOLE SULPHONAMIDE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS 6 AND PHARMACEUTICAL COMPOSITION CONTAINING THEREOF | 2016 |
|
RU2697665C1 |
1,3,4-OXADISOLAMIDE DERIVATIVE COMPOUND AS HISTONE DEACETYLASE 6 INHIBITOR AND PHARMACEUTICAL COMPOSITION CONTAINING THEREOF | 2016 |
|
RU2700696C2 |
NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR AND PHARMACEUTICAL COMPOSITION CONTAINING THEREOF | 2021 |
|
RU2817736C1 |
GCN2 INHIBITORS AND THEIR USE | 2019 |
|
RU2811408C2 |
HETEROAROMATIC MODULATORS OF RETINOL-BOUND ORPHAN GAMMA RECEPTOR | 2017 |
|
RU2771280C2 |
OXADIAZOLAMINE DERIVATIVES AS HISTONE DEACETYLASE 6 INHIBITOR AND PHARMACEUTICAL COMPOSITION CONTAINING THEM | 2016 |
|
RU2695133C1 |
Authors
Dates
2023-03-31—Published
2020-05-29—Filed